At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ICCM IceCure Medical Ltd.
Market Closed 08-14 16:00:00 EDT
3.02
+0.02
+0.67%
盘后2.90
-0.12-3.97%
19:18 EDT
High3.20Low2.96Vol50.76K
Open3.04D1 Closing3.00Amplitude8.00%
Mkt Cap10.35MTradable Cap6.63MTotal Shares3.43M
T/O152.88KT/O Rate2.31%Tradable Shares2.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

IceCure Medical Expands 2024 Employee Equity Plan With 2.5 Million Additional Shares
TIPRANKS  ·  08-15 04:48
IceCure Medical Expands 2024 Employee Equity Plan With 2.5 Million Additional Shares
IceCure Expands 2024 Employee Equity Plan Share Reserve to 2,612,667 Shares
Reuters  ·  08-15 04:17
IceCure Expands 2024 Employee Equity Plan Share Reserve to 2,612,667 Shares
Lifeward Ltd Q2 Revenue up 16% on Higher ReWalk Personal Exoskeleton Sales
Reuters  ·  08-14 21:26
Lifeward Ltd Q2 Revenue up 16% on Higher ReWalk Personal Exoskeleton Sales
Hubei Native Yuan Xinyi Awarded Major International Prize Worth Approximately 7 Million Yuan
Deep News  ·  08-14 11:21
Hubei Native Yuan Xinyi Awarded Major International Prize Worth Approximately 7 Million Yuan
IceCure Highlights 5-Year ICE3 Breast Cancer Trial Showing 3.1% Recurrence Rate After Cryoablation
Reuters  ·  08-13
IceCure Highlights 5-Year ICE3 Breast Cancer Trial Showing 3.1% Recurrence Rate After Cryoablation
Israel's MediWound Beats Q2 Revenue Estimates, Reaffirms 2026 Guidance
Reuters  ·  08-13
Israel's MediWound Beats Q2 Revenue Estimates, Reaffirms 2026 Guidance
Finland's Bioretec H1 Revenue Rises 12%, Loss Narrows
Reuters  ·  08-13
Finland's Bioretec H1 Revenue Rises 12%, Loss Narrows
Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook
Reuters  ·  08-13
Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook
Icecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate
Benzinga Earnings  ·  08-12
Icecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate
Icecure Medical Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Icecure Medical Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary
Israel's IceCure Medical H1 Revenue Rises on Higher System, Probe Sales
Reuters  ·  08-12
Israel's IceCure Medical H1 Revenue Rises on Higher System, Probe Sales
IceCure Net Loss Widens to USD 8.78 Million in H1 FY26; Revenue Rises 45% to USD 1.82 Million
Reuters  ·  08-12
IceCure Net Loss Widens to USD 8.78 Million in H1 FY26; Revenue Rises 45% to USD 1.82 Million
Icecure Reports Its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-over-Year
THOMSON REUTERS  ·  08-12
Icecure Reports Its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-over-Year
Icecure Medical H1 Revenue USD 1.8 Million
THOMSON REUTERS  ·  08-12
Icecure Medical H1 Revenue USD 1.8 Million
Press Release: IceCure Reports Its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-over-Year
Dow Jones  ·  08-12
Press Release: IceCure Reports Its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-over-Year
IceCure Medical Announces Board Change and New Independent Director
TIPRANKS  ·  08-12
IceCure Medical Announces Board Change and New Independent Director
IceCure Adds Adventist Health Glendale as Enrolling Site for ChoICE Breast Cancer Cryoablation Study
Reuters  ·  08-06
IceCure Adds Adventist Health Glendale as Enrolling Site for ChoICE Breast Cancer Cryoablation Study
IceCure Medical Schedules First-Half Financial and Operating Results Release, Conference Call
Reuters  ·  08-05
IceCure Medical Schedules First-Half Financial and Operating Results Release, Conference Call
Icecure: Sio Petitions Nccn to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance of Prosense®
THOMSON REUTERS  ·  07-29
Icecure: Sio Petitions Nccn to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance of Prosense®
IceCure Launches ChoICE Post-marketing Study of ProSense Cryoablation for Low-risk Breast Cancer in US
Reuters  ·  07-27
IceCure Launches ChoICE Post-marketing Study of ProSense Cryoablation for Low-risk Breast Cancer in US

Introduction

Company Name.
IceCure Medical Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Issue price:
--